
Some babies really are born fussy, expert reveals - and there's not much parents can do about it
Researchers have discovered that DNA accounts for a large portion of how much babies cry and how easily they calm down.
The findings might provide some reassurance for exhausted families, who feel like they've tried everything to get their youngster to settle.
However, it suggests that not much can be done to combat the issue.
The team, from Uppsala University in Sweden, tracked 998 twins at two months and five months old.
By comparing identical twins, who share 100 per cent of their DNA, with fraternal twins, who share around half of their DNA, they were able to separate genetic influences from environmental ones.
The researchers asked parents questions about the children's sleep, crying and ability to settle.
Their analysis, published in the journal JCPP Advances, revealed that at the age of five months genetic factors explained up to 70 per cent of the differences in crying duration among babies.
Dr Charlotte Viktorsson, postdoctoral fellow in psychology and lead author of the study, said: 'What we found was that crying is largely genetically determined.
'At the age of two months, the children's genetics explain about 50 per cent of how much they cry. At five months of age, genetics explain up to 70 per cent of the variation.
'For parents, it may be a comfort to know that their child's crying is largely explained by genetics, and that they themselves have limited options to influence how much their child cries.'
The study found a baby's ability to settle down was also largely determined by their DNA, accounting for up to 67 per cent of the variation between infants.
'How rapidly the infant settled was primarily due to the environment at two months of age, but by five months their genetics had gained some significance,' Dr Viktorsson explained.
'This reflects the rapid development that occurs in infants, and may indicate that parents' efforts in getting their child to settle may have the greatest impact in the first months.'
However, genetics played less of a role when it came to how many times the children woke up during the night.
This was mainly influenced by environmental factors, they discovered, such as sleep routines and the environment in which the child sleeps.
Researchers from the RIKEN Centre for Brain Science in Japan claim that the trick to soothe a crying infant is carrying them in your arms for five minutes, then sitting with them in your arms for five to eight minutes, before placing them in their crib
A study has previously claimed to have the 'recipe' to lull a baby to sleep - and it's surprisingly simple.
From offering a pacifier to desperately singing lullabies, most exhausted parents will go to any lengths to get their baby to stop crying.
But researchers from the RIKEN Centre for Brain Science in Japan claim that the trick to soothe a crying infant is to carry them in your arms for five minutes, then sit with them in your arms for five to eight minutes, before placing them in their cot.
The team hopes the method will provide an immediate solution for crying infants, although they're unsure whether it will improve sleep in the long-term.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
41 minutes ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
2 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.


The Independent
6 hours ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.